bullish
I-Mab (IMAB US): Expanding Commercialization Footprint in China for Innovative Late-Stage Assets
242 Views22 Nov 2021 22:47
SUMMARY
- I-Mab (IMAB US) shares gained 19% in last 10 days after the company announced commercial partnering deal for its pediatric growth hormone deficiency drug candidate, Eftansomatropin Alfa in China.
- Oncology drug, felzartamab is expected to be I-Mab’s first drug in China. Last month, I-Mab entered into a partnership with Sinopharm to extend coverage and enhance accessibility of its pipeline.
- To expand its investor base, I-Mab is expected to complete dual listing on the STAR Market of the Shanghai Stock Exchange by the end of 2022.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
- I-Mab (IMAB US): Expanding Commercialization Footprint in China for Innovative Late-Stage Assets22 Nov 2021
- I-Mab (IMAB US) - Insights On Core Products TJC4, TJ202 and TJ10129 Mar 2021
- I-Mab (天境生物) Lock-Up Expiry: A Differentiated Immunotherapy Player Worth Reverse Inquiry08 Jul 2020
- Autonomous Driving- Are We There Yet?20 Mar 2018
x